; (ii) such applications pending with the Office of Generic Drugs that did not meet the goals for the corresponding fiscal year and the future plans of the Food and Drug Administration to meet these goals; and (iii) the most common causes within the agency for missing such goals. (B) Relevant data to determine whether the Office of Generic Drugs has met the performance enhancement goals for the corresponding fiscal year. (C) External or other circumstances impacting the Office of Generic Drugs or the Food and Drug Administration that impacted the ability of the agency to meet review time and performance enhancement goals. . (2) Issuance of corrective action reports Section 744C of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–43 ) is amended— (A) by redesignating subsections (c) and (d) as subsections (e) and (f), respectively